Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    bioadaptor
Previous Study | Return to List | Next Study

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (BIOADAPTOR RCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04192747
Recruitment Status : Recruiting
First Posted : December 10, 2019
Last Update Posted : October 8, 2021
Sponsor:
Information provided by (Responsible Party):
Elixir Medical Corporation

Brief Summary:
The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Coronary Artery Stenosis Coronary Disease Coronary Stenosis Device: Percutaneous Coronary Intervention Not Applicable

Detailed Description:

The Bioadaptor RCT Study is a prospective, 1:1 randomized study of parallel designed, that will enroll up to 444 patients requiring treatment of up to two de novo coronary lesions of ≤ 34 mm in length in vessels of ≥ 2.25 mm and ≤ 4.0 mm in diameter.

One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the ELX1805J (DynamX Bioadaptor) or Resolute Onyx stent

The primary safety endpoint is Target Lesion Failure (TLF) at 12 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization

Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months and 2-5 years.

Using visual assessment, the target lesion must measure ≥ 2.25 mm and ≤ 4.0 mm in diameter and ≤ 34 mm in length able to be covered by a single ELX1805J or Resolute Onyx stent including 2 mm of healthy vessel on either side of the planned treatment area.

The patient will be eligible for device implantation only after satisfactory lesion pre-dilatation defined as: ≥ TIMI 2 flow, and no dissection greater than Grade B (NHLBI) able to be covered with a single device

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 444 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-blind, 1:1 Randomized trial of parallel design
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805
Actual Study Start Date : December 16, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2026

Arm Intervention/treatment
Experimental: Elixir Bioadaptor (ELX1805J)
The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
Device: Percutaneous Coronary Intervention
Percutaneous coronary intervention of de novo native coronary artery lesions

Active Comparator: Medtronic Resolute Onyx Stent
The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length
Device: Percutaneous Coronary Intervention
Percutaneous coronary intervention of de novo native coronary artery lesions




Primary Outcome Measures :
  1. Number of Patients with Target Lesion Failure (TLF) [ Time Frame: 12 Months ]
    TLF is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated


Secondary Outcome Measures :
  1. Number of Patients with Target Lesion Failure (TLF) [ Time Frame: 30 Days, 180 Days, 2, 3, 4 and 5 years ]
    TLF is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated

  2. Number of Patients with Patient Oriented Clinical Endpoint [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Overall cardiovascular outcomes from the patient's perspective. This endpoint is a composite endpoint that includes all-cause mortality (cardiac and non-cardiac), stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)

  3. Number of Patients with Composite of All-cause mortality [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    A composite of all-cause mortality, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)

  4. Number of Patients with Composite of Cardiac Death TVMI and ID-TVR revascularization [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Composite of cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR)

  5. Number of Patients with Cardiac death, stroke, MI and revascularization [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Composite of cardiac death, stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)

  6. Number of Patients with Cardiac death, MI and revascularization [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Composite of cardiac death, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)

  7. Number of Patients with Ischemia Driven Target Lesion Revascularization (ID-TLR) [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Ischemia driven target lesion revascularization

  8. Number of Patients with Target Lesion Revascularization (TLR) [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Target lesion revascularization

  9. Number of Patients with Target Vessel Revascularization (TVR) [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications

  10. Number of Patients with Ischemia driven TVR (ID-TVR) [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Re-PCI or CABG in the target vessel due to restenosis or other complications

  11. Number of Patients with Revascularization (target vessel or non-target vessel) [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications

  12. Number of Patients with Q-wave MI [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    CK post procedure is twice the upper limit of the reference value or higher, with new pathological Q-wave on 2 or more contiguous ECG leads and if CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.

  13. Number of Patients with Non Q-wave MI [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    CK post procedure is twice the upper limit of the reference value or higher, without new pathological Q-waves. If CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.

  14. Number of Patients with MI (target vessel or non-target vessel) [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    per ARC II

  15. Number of Patients with Target Vessel MI [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    per ARC II

  16. Number of Patients with All-cause Death [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Per ARC II Definitions

  17. Number of Patients with Cardiac Death [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Per ARC II Definitions

  18. Number of Patients with Composite of Cardiac Death or Target Vessel MI [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Target Vessel Related Death or MI

  19. Number of Patients with Composite of all-cause Death or MI [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    target vessel or non-target vessel related death or MI

  20. Number of Patients with Composite of all-cause Death, MI (target vessel or non-target vessel), or TVR [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Any Death, any MI and any Target Vessel Revascularization

  21. Number of Patients with Composite of Probable or Definite Stent Thrombosis [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Per ARC II Definitions

  22. Number of Patients with Probable Stent Thrombosis [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Per ARC II Definitions

  23. Number of Patients with Definite Stent Thrombosis [ Time Frame: 30 Days, 180 Days, 1, 2, 3, 4 and 5 years ]
    Per ARC II Definitions



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Inclusion Criteria

Patients who meet all of the following criteria are eligible:

  1. Patient must be ≥ 20 years of age.
  2. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
  3. Patients who are able to take dual anti-platelet therapy for 1 year following the index procedure and anticoagulants prior to/during the index procedure.
  4. The subject is an acceptable candidate for Percutaneous Transluminal Coronary Angioplasty (PTCA), stenting, and emergent Coronary Artery Bypass Graft (CABG) surgery.
  5. The subject or subject's legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board or Ethics Committee of the respective clinical site.
  6. Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing
  7. Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing
  8. Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure
  9. Target lesion(s) must be de novo and located in a native coronary artery with a vessel mean diameter of ≥ 2.25 and ≤ 4.0 mm.
  10. Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 100% with a TIMI flow of > 1. When two target lesions are treated, they must be located in separate major epicardial vessels
  11. visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 14/15/18/23/28/32/38 mm ELX1805J stent and have at least 2 mm of healthy vessel on either side Or
  12. The visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 15/18/22/30/34/38 mm ZES stent respectively and have at least 2 mm of healthy vessel on either side.
  13. The lesion(s) must be successfully pre-dilated prior to enrollment Mandatory pre-dilatation includes the use of 2 orthogonal views to confirm lesion inclusion and exclusion criteria and successful pre-dilatation defined as balloon inflation without waist and a lumen diameter no less than 0.5 mm smaller than the vessel diameter.
  14. Percutaneous intervention of lesions in a non-target vessel if:

    • Not part of a another clinical investigation
    • ≥ 30 days prior to the study index procedure
    • ≥ 6 months after the study index procedure (planned)
  15. Percutaneous intervention of lesions located in the target vessel if:

    • Not part of a clinical investigation
    • ≥ 6 months prior to the study index procedure
    • >12 months after the study index procedure (planned)
    • Previous intervention was distal to and >10 mm from the target lesion

Exclusion Criteria:

  1. The patient was diagnosed with an acute myocardial infarction within the past 72 hours and the CK and CKMB have not returned to normal (or cTn >15x ULN) and the patient is experiencing clinical symptoms indicative of ongoing ischemia
  2. Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, cobalt, nickel, chromium, molybdenum, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
  3. Patients with a history of allergic reaction or serious hypersensitivity to drugs exhibiting interactions with sirolimus, zotarolimus, everolimus, tacrolimus, temsirolimus, biolimus and other rapamycin, derivatives or analogues) or similar drugs
  4. Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors.
  5. Patient presenting with chronic (permanent) atrial or ventricular arrhythmia or current unstable ventricular arrhythmias
  6. Patient has a known left ventricular ejection fraction (LVEF) < 30%
  7. Patient has received a heart or other organ transplant or is on a waiting list for any organ transplant
  8. Patient has a malignancy that is not in remission.
  9. Patient is receiving immunosuppression therapy other than steroids and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
  10. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures.
  11. Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected to have cirrhosis of Child-Pugh ≥ Class B within 7 days before study procedure
  12. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL within 7 days before study procedure, or patient on dialysis)
  13. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  14. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
  15. Patient has had a significant GI or urinary bleed within the past six months
  16. Patient has severe symptomatic heart failure (i.e., NYHA class IV)
  17. Patient has a medical condition that precludes safe 6 French sheath insertion
  18. Patient has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
  19. Patient is already participating in another clinical research study which has not reached the primary endpoint (long-term follow-up is not an exclusion)
  20. Other patients whom primary investigator or subinvestigator determined to be ineligible for this clinical study
  21. Patients with bypass graft to the target vessel or lesion is located in a bypass graft
  22. Patients with stent implanted within 10 mm of proximal or distal end of target lesion
  23. Patients with a target lesion involving a bifurcation of which the side branch will be jailed by the struts and:

    • Side branch ≥ 2.5 mm in diameter,
    • Side branch requiring predilatation (including Kissing Balloon Technique), or
    • Side branch has an ostial lesion or lesion with > 50% stenosis
  24. Patients suspected or confirmed with the QCA analysis of having stenotic lesion of more than 50% in target vessel in addition to target lesion
  25. Patients with target lesion in ostia located within 5 mm of origin of LAD, LCX or RCA
  26. Patients with stenotic lesion in left main trunk
  27. Patients with target lesion that is a chronic total occlusion (CTO) or ≤ TIMI 1 coronary flow in the target vessel
  28. Patients with target vessel that contains thrombus as indicated in pre-procedure angiographic, IVUS or OCT images
  29. Excessive tortuosity ≥ two 45° angles or extreme angulation (≥ 90°) proximal to or within the target lesion
  30. Patients with target vessel that has moderate to severe calcification that prevents complete angioplasty balloon (POBA with non-compliant balloon, or scoring balloon,) inflation or requires other devices such as rotational atherectomy, rotoblator.
  31. Patients with dissection of Grade A or B that cannot be covered (including 2mm distal to the dissection) with a single study device or with dissection of Grade C or higher
  32. Patients with 2 or more target lesions on 1 branch or target lesions on 3 branches that need to be treated during study procedure
  33. Target lesion involves a myocardial bridge

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04192747


Contacts
Layout table for location contacts
Contact: Tina Cordaro, RN, BSN, MPA +1 (585) 360-7270 tcordaro@elixirmedical.com
Contact: Candace Elek, MS +1 (408) 636-2020 celek@elixirmedical.com

Locations
Show Show 36 study locations
Sponsors and Collaborators
Elixir Medical Corporation
Investigators
Layout table for investigator information
Principal Investigator: Shigeru Saito, MD Chief Director, Shonan Kamakura General Hospital
Layout table for additonal information
Responsible Party: Elixir Medical Corporation
ClinicalTrials.gov Identifier: NCT04192747    
Other Study ID Numbers: ELX-CL-1805
First Posted: December 10, 2019    Key Record Dates
Last Update Posted: October 8, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Elixir Medical Corporation:
Coronary Ste
Bioadaptor
Percutaneous Coronary Intervention
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Coronary Stenosis
Constriction, Pathologic
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Pathological Conditions, Anatomical